Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
06:51pm, Wednesday, 06'th Nov 2024
Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relatio
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
01:01pm, Wednesday, 06'th Nov 2024
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Wednesday, 06'th Nov 2024
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wal
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates
09:10am, Wednesday, 06'th Nov 2024
Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
08:30am, Wednesday, 06'th Nov 2024
Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients f
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 30'th Oct 2024
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again
01:10pm, Tuesday, 29'th Oct 2024
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
10:30am, Tuesday, 22'nd Oct 2024
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
09:55am, Friday, 18'th Oct 2024
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
Charles River Launches New Retrogenix® Non-Human Protein Library
08:00am, Thursday, 17'th Oct 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selec
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
04:30pm, Wednesday, 16'th Oct 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
10:10am, Thursday, 10'th Oct 2024
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform
11:26am, Tuesday, 08'th Oct 2024
BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution.
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
06:00am, Thursday, 19'th Sep 2024
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today anno
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
09:11am, Wednesday, 18'th Sep 2024
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
